- Company ends Phase 4 observational registry early as data achieved statistical significance for non-inferiority in premature neonates compared to term and near-term neonates at planned interim ...

Mallinckrodt announced that the phase 4 observational registry study evaluating INOmax® (nitric oxide) gas, for inhalation, in preterm neonates with pulmonary hypertension was stopped early due to ...

-- INOMAX® DS and INOMAX® DSIR Now Compatible with Nearly 60 Respiratory Care Devices -- Hampton, NJ, March 21, 2012 – Ikaria, Inc., a critical care company focused on developing and commercializing ...

- Chart review is expected to collect real-world data on patients with respiratory complications associated with COVID-19 who received INOmax® (nitric oxide) gas, for inhalation in a hospital setting ...

– Company's next generation nitric oxide delivery system combines mini-cylinder technology, automation, integration, and interaction into one device 1 – – The INOmax EVOLVE DS also earned recognition ...

April 30 (Reuters) - Mallinckrodt Plc said on Thursday it would fund a trial conducted by medical experts, evaluating the potential benefits of its respiratory therapy, INOmax, as a treatment for lung ...

CLINTON, N.J., Nov. 27 Ikaria Holdings, Inc., through itssubsidiary INO Therapeutics LLC, announced today that it has received approvalfrom Australia's regulatory body, the Therapeutic Goods ...

Affected serial numbers include DS20070005-DS20100865. This product was manufactured from March 12, 2007 through February 2, 2011 and distributed from September 4, 2007 through February 2, 2011.

Type: Inhaled nitric oxide (iNO) indicated in the U.S. for term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Status: Mallinckrodt said April 30 it ...